HUTCHMED (NASDAQ:HCM) Stock Price Up 8.3% – Still a Buy?

by · The Cerbat Gem

Shares of HUTCHMED (China) Limited (NASDAQ:HCM – Get Free Report) were up 8.3% during mid-day trading on Tuesday . The stock traded as high as $12.72 and last traded at $13.15. Approximately 48,337 shares were traded during mid-day trading, a decline of 55% from the average daily volume of 107,565 shares. The stock had previously closed at $12.14.

Analysts Set New Price Targets

Separately, StockNews.com upgraded HUTCHMED from a “hold” rating to a “buy” rating in a research report on Friday, March 21st.

Get Our Latest Research Report on HCM

HUTCHMED Stock Down 2.0 %

The business has a 50-day moving average price of $14.75 and a 200 day moving average price of $16.19. The company has a current ratio of 2.81, a quick ratio of 2.68 and a debt-to-equity ratio of 0.07.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in HCM. Jane Street Group LLC increased its stake in HUTCHMED by 362.2% during the third quarter. Jane Street Group LLC now owns 62,997 shares of the company’s stock worth $1,305,000 after acquiring an additional 49,366 shares during the last quarter. State Street Corp boosted its holdings in shares of HUTCHMED by 0.9% in the 3rd quarter. State Street Corp now owns 349,524 shares of the company’s stock worth $6,826,000 after purchasing an additional 3,078 shares during the period. ABC Arbitrage SA bought a new position in shares of HUTCHMED during the 4th quarter valued at approximately $500,000. XY Capital Ltd purchased a new stake in HUTCHMED during the 4th quarter valued at $673,000. Finally, Crossmark Global Holdings Inc. lifted its position in HUTCHMED by 10.7% in the fourth quarter. Crossmark Global Holdings Inc. now owns 18,591 shares of the company’s stock worth $268,000 after buying an additional 1,799 shares during the last quarter. Institutional investors own 8.82% of the company’s stock.

About HUTCHMED

(Get Free Report)

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.

Further Reading